Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
Inhaled IL-4 halts neuron destruction in MS models
Latest NewsAn US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system.
Mission Therapeutics promotes Paul Thompson to VP
AppointmentsToday Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
Convert Pharmaceuticals SA closes €13.6m Series A round
Latest NewsLiège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and funds from the European Eurostars programme.
Rentschler Biopharma appoints Federico Pollano as Senior VP of Business Development
AppointmentsRentschler Biopharma SE, a service provider for biopharmaceuticals, today announced the appointment of Mr. Federico Pollano as the new Senior Vice President of Business Development, effective March 1.
Novo Holdings launches €135m fund to combat antimicrobial resistance
Latest NewsEU-Commission appoints Jean-Eric Paquet
AppointmentsPaquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation
Mereo BioPharma Appoints Wills Hughes-Wilson
AppointmentsMereo BioPharma Group plc, a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, today announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning.
Bavarian Nordic and AZ combine cancer jab with durvalumab
Latest NewsAstraZeneca (AZ) and Bavarian Nordic (BN) combine BN’s cancer vaccine CV301 and AZ’s PD-L1 checkpoint blocker durvalumab in an investigator-sponsored trail to check synergistic effects in patients with colorectal and pancreatic cancer overexpressing CEA and MUC-1.
EMA recommends two orphan drugs for approval
Latest NewsThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended three medicines, two thereof orphan drugs, at its February 2018 meeting.
Bioeconomy: Bringing in the public
Latest NewsEverybody wants green production. Bioeconomy progress, however, must become more visible to consumers and let the civil society get involved to ensure socially robust innovation and perception, according to the BioBioSTEP project.